Table 3.

Overall survival and cancer treatment switch with antibiotic use compared with non-use expressed as a synergy factor between ICI/TKI use

	All-cause mortality	Death or cancer treatment switch
	Effect of antibiotic use	Effect of antibiotic use
	Synergy index (ICI vs TKI)	Synergy index (ICI vs TKI)
No antibiotics
Antibiotic use prior to start of cancer therapy
≤30 days before	0.96 (0.70 to 1.31)	0.93 (0.68 to 1.26)
By underlying malignant diagnosis
Malignant melanoma	0.85 (0.49 to 1.48)	0.75 (0.43 to 1.31)
Non-small cell lung cancer	0.97 (0.70 to 1.34)	0.92 (0.63 to 1.33)
By route of administration
Oral	0.85 (0.63 to 1.15)	0.90 (0.64 to 1.25)
Intravenous	1.23 (0.58 to 2.60)	0.89 (0.41 to 1.92)
By concomitant use of systemic corticosteroids
No	1.00 (0.68 to 1.46)	1.08 (0.74 to 1.59)
Yes	0.86 (0.57 to 1.30)	0.65 (0.38 to 1.10)

ICI, immune checkpoint inhibitor; TKI, tyrosine kinase inhibitor.